Davide Ceresa

Davide Ceresa

Auto-generated profile, based on publicly available information

Davide Ceresa

Department of Experimental Medicine, University of Genova , Genova

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
FPFrancesca Piaggio
Francesca Piaggio
CRChiara Riviera
Chiara Riviera
FAFrancesco Alessandrini
Francesco Alessandrini
DMDaniela Marubbi
Daniela Marubbi
DCDavide Ceresa
Davide Ceresa
PMPaolo Malatesta
Paolo Malatesta
Background: Glioblastoma is an aggressive tumor with poor prognosis and limited treatment options due to its resistance to chemotherapy and radiotherapy, high heterogeneity, and ability to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evaluate the therapeutic efficacy of an engineered oncolytic Herpes Simplex Virus for glioblastoma treatment. Methods: We investigated the efficacy of R-115, a retargeted oncolytic Herpes Simplex Virus directed against the human epidermal growth factor receptor 2 (HER2) and engineered to express murine interleukin-12, in an immunocompetent glioblastoma model that recapitulates HER2 tumor heterogeneity. We tested the translatability and reliability of R-115 by assessing overall survival in HER2 + or HER2 + /HER2 − mixed tumors treated with different schedules. We assessed the potential of the treatment to elicit an antitumor vaccination effect by rechallenging previously treated mice with HER2-negative cells in the absence of any further therapy. Additionally, we characterized both the immune and tumor components by analyzing immune cells’ proliferation, activation and the resulting tumor cells reduction. Results: R-115 exhibited potent cytotoxic and immune-stimulatory effects, significantly prolonging survival and eradicating tumors in approximately 25% of treated mice independently from tumor composition and treatment schedule. Furthermore, it induced long-term immune memory, enabling the eradication of secondary transplanted tumors, effectively acting as a tumor-agnostic vaccination. Notably, in addition to the direct oncolysis mediated by the virus, R-115 treatment induced an immune response even against HER2-negative glioblastoma cells, potentially via cross-presentation or epitope spreading. Conclusions: Our findings candidate R-115 as a promising alternative to standard glioblastoma treatments and support further investigation to advance its clinical application.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Carolina BalbiCarolina Balbi
Carolina Balbi
DCD Ceresa
D Ceresa
CSC Schiano
C Schiano
PMPaolo Malatesta
Paolo Malatesta
Lucio BarileLucio Barile
Lucio Barile
GVG Vassalli
G Vassalli
Introduction: Neonatal rats have the capacity to regenerate their hearts in response to injury, but this potential is lost after the first week of life. Cardiac maturation lays the foundation for postnatal heart development and disease, yet little is known about the contributions of the microenvironment to cardiomyocyte maturation. Extracellular vesicles (EV) are bilayer-membrane nanoparticles released by all cell types, carrying proteins, lipids, and nucleic acids, which reflect the activation state of parental cells. Secreted small extracellular vesicles (sEV), prominently figure among extracellular signals that regulate cell function. Purpose: We aim to determine whether cardiomyocyte (CM) derived sEV carried miRNA that has a role in heart development with specific regards to cardiomyocyte maturation. Methods: sEV were isolated from rat cardiomyocyte at day 0 and 7 after birth by serial ultracentrifugation. sEV were characterized by NTA and analyzed by Western blot for the presence of classical EV markers (TSG101, Syntenin-1). The role of sEV in cardiomyocyte proliferation was assessed by analysis of EdU incorporation on neoantal rat CM treated with sEV_p0 or sEV_p7. miRNA content on sEV was assessed using a rat-miRNome MicroRNA Profiling Kit and the identified miRNA's targets confirmed by RealTime-PCR and Western Blot. Results: NTA and Western Blot analysis confirmed the presence of sEV in both the extracellular vesicles preparation. sEV_p0 showed to be able to sligtly increase EdU incorporation in treated cardiomyocyte (1.15-Fold) while sEV_p7 significantly inihibit CM proliferation (0.78-Fold) toghether with a change in cardiomyocyte citoscheletal architecture. Data from miRNome analysis showed in sEV_p7 a significan increase in miRNA with cyclines as tagets. Downregulation of Cdk1; Cdk4; Cdk2; CcnB1 and CcnD1 was confirmed on CM trated with sEV_p7 compared to Ctrl. Downregulation of CCND1 was aslo confrmed at the protein level by Western Blot analysis. Conclusions: These preliminary resultes showed an important role in heart develompent of cardiomyocyte derived-sEV. A deeper investigation of the pathaway activated by sEV may have a potential interest for the identification of possible regulators for stimulating heart regeneration. Funding Acknowledgement: Type of funding sources: Foundation. Main funding source(s): Fondazione Leonardo, Lugano, Switzerland

26 October 2026 in European Heart Journal Open
Verified
Journal Article
Open access
EBEva Bianconi
Eva Bianconi
ANTONELLA DE PALMAANTONELLA DE PALMA
ANTONELLA DE PALMA
DPDavide Perico
Davide Perico
SBsilvia bruno
silvia bruno
FFFrancesca Fumagalli
Francesca Fumagalli
PAPietro Ameri
Pietro Ameri
Aims: Previous studies found increased cancer incidence in patients with heart failure with reduced ejection fraction (HFrEF). We sought to explore the biological correlates of the association of HFrEF with cancer in humans. Methods and results: Among participants in the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca—Heart Failure (GISSI-HF) trial with HFrEF and available baseline plasma samples, we selected those who developed solid cancer (cases) and matched them with controls without cancer by age, sex, New York Heart Association class, and follow-up duration. We isolated the plasma extracellular vesicle (EV)-enriched fraction, in which EVs were confirmed by western blot for CD9, FLOTILLIN-1, ALIX, and TSG101, and by nanoparticle tracking analysis (mean particle diameter <200 nm). The protein content of EV preparations was characterized by nanoliquid chromatography-high=resolution tandem mass spectrometry. Of the 940 identified proteins, 148 were differentially expressed between EV preparations from cases (EVs-cases) and controls (EVs-controls) and were related to biological functions implicated in cancer growth, particularly apoptosis and spliceosome/transcriptome regulation. Next, we explored the effects of EVs-cases and EVs-controls in MCF7 breast cancer cells and ran confirmatory experiments with another two cell lines, HCT116 (colon) and A549 (lung). Apoptosis, as determined by caspase 3 cleavage, was blunted by EVs-cases in MCF7, but not in HCT116 and A549 cells. Screening qPCR identified NR3C1, encoding the glucocorticoid receptor, as a spliceosome/transcription modulator affected by EVs-cases. Targeted qPCR confirmed that it was reduced by EVs-cases in A549 cells. Conclusion: Circulating EV-enriched fractions from patients with HFrEF and incident cancer have a distinct proteomic signature and might modulate human cancer cell biology.

30 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DVDavide Visigalli
Davide Visigalli
Mattia CameraMattia Camera
Mattia Camera
DCDavide Ceresa
Davide Ceresa
GCGiovanna Capodivento
Giovanna Capodivento
DMDaniela Marubbi
Daniela Marubbi
LNLucilla Nobbio
Lucilla Nobbio
Charcot–Marie–Tooth type 1A (CMT1A) is the most common inherited peripheral neuropathy, caused by duplication of the peripheral myelin protein 22 ( PMP22 ) gene and characterized by dysmyelination and defects in myelin maturation. Hypercellularity is a prominent feature of the disease, although its origin, persistence, and underlying mechanisms remain controversial. Here, we performed a longitudinal analysis of sciatic nerves from wild-type (WT) and CMT1A rats between 2 and 12 months of age. We demonstrated that CMT1A nerves exhibit persistent cellular proliferation extending into adulthood. This phenotype is confirmed by bulk RNA-seq data showing sustained enrichment of proliferation-associated gene signatures. Cell-type signature analysis identifies overrepresentation of immature, neural crest-related, and epithelial-mesenchymal transitional (EMT) transcriptional programs in CMT1A nerves. Among the most upregulated genes, RUNX2 showed strong and prolonged expression at both transcript and protein levels. Consistently with the key role of RUNX2 in the activation of the injury response, CMT1A nerves also showed a marked enrichment in SOX10 + /JUN + cells, that only partially overlap with SOX10 + /RUNX2 + cells, indicating a maladaptive activation of the injury-like Schwann cell (SC) program. Interestingly, we detected robust upregulation of SMOC2, an extracellular matrix protein selectively expressed by endoneurial fibroblasts, pointing to activation of non-canonical cell types and altered extracellular matrix remodeling. Together, these data demonstrate that CMT1A peripheral nerves are characterized by chronic hypercellularity driven by persistent proliferation, EMT, and dysregulated injury transcriptional programs, collectively pointing at progressive and multicellular nerve remodeling as a relevant pathomechanism in the disease. Highlights: CMT1A nerves exhibit persistent proliferation throughout adulthood CMT1A induces immature and injury prone transcriptional programs RUNX2 marks a distinct Schwann cell subpopulation in CMT1A nerves Endoneurial fibroblasts contribute to progressive nerve remodeling

29 October 2025 in The FEBS Journal
Verified
Journal Article
Open access
Maria Rosaria CoppolaMaria Rosaria Coppola
Maria Rosaria Coppola
DBDeianira Bellitto
Deianira Bellitto
EAErfan Asgari
Erfan Asgari
VBVirginia Bazzurro
Virginia Bazzurro
GCGiorgia Casucci
Giorgia Casucci
MTMichela Tonetti
Michela Tonetti
Catel–Manzke syndrome (CMS) is a rare genetic disorder associated with mutations in the TDP‐glucose 4,6‐dehydratase ( TGDS ) gene, the function of which in vertebrates remains unclear. This study investigated the zebrafish ortholog tgds to assess its suitability for modeling the disease. During development, the tgds transcript exhibits a conserved biphasic expression pattern with an initial maternal contribution followed by a second wave of expression after gastrulation. Recombinant zebrafish Tgds expressed in Escherichia coli demonstrated UDP‐D‐glucose 4,6‐dehydratase ( EC4.2.1.76 ) activity, similar to TGDS orthologs in lower eukaryotes, where it acts as the first step in the L‐rhamnose biosynthetic pathway. This finding suggests the presence of a yet unidentified pathway in vertebrates. Furthermore, CMS‐associated mutations in conserved residues significantly impair enzyme activity and stability. CRISPR/Cas9‐mediated F 0 knockout of tgds resulted in a range of developmental defects in zebrafish. In particular, craniofacial cartilage alterations, associated with a decrease in sulfate glycosaminoglycan content, mirrored some skeletal features observed in humans with CMS. These findings establish the zebrafish as a relevant model to further explore CMS pathogenesis and the in vivo function of tgds .